NEW DIRECTIONS IN THYROID CANCER RESEARCH AND TREATMENT

甲状腺癌研究和治疗的新方向

• 批准号: 7501452
• 负责人: SAMUEL A WELLS
• 金额: $ 0.75万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-27 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7501452
• 关键词: Advocate; Cancer Biology; Caring; Chromosomal Rearrangement; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Commit; Development; Drug Industry; Gene Mutation; Genomics; Grant; Incidence; International; Malignant Neoplasms; Malignant neoplasm of thyroid; Medicine; Metabolic Pathway; Mission; Mutation; Oncology Group; Patients; Rare Diseases; Rate; Research; Scientist; Series; Societies; Solid Neoplasm; Therapeutic Agents; Thyroid Gland; Thyroid carcinoma; United States; Universities; Washington; anticancer research; base; interest; lectures; posters; preclinical study; programs; skills

DESCRIPTION (provided by applicant): The long-term objective of the series of educational programs, "New Directions in Thyroid Cancer Research and Treatment", is to provide basic and clinical scientists, with an understanding of important advances in thyroid cancer biology and clinical care. There are several reasons why a focused educational initiative of this subject is timely and needed. There will be approximately 30,000 new cases of thyroid cancer in the United States in 2007. One might consider this malignancy a rare disease, however, for unknown reasons the incidence of thyroid cancer is increasing at a rate more rapid than that of any other solid tumor. Most importantly, over the last two decades, the mutations, or chromosomal rearrangements causing the major histological types of thyroid cancer have been identified. These and similar discoveries in other solid tumors, have stimulated the pharmaceutical industry to develop therapeutic agents, which target either the genetic mutation, or the metabolic pathway activated by the mutation. Some targeted therapies for thyroid cancer have already shown activity in preclinical studies, and even in early clinical trials. These new therapies have great promise for patients with locally advanced or metastatic thyroid cancer. Moreover, these therapies represent a prime example of "personalized genomic medicine". Currently no society or association has as its primary mission the development and offering of educational programs in thyroid cancer. Two years ago, recognizing the need for broad based educational programs in thyroid cancer, a group of committed basic scientists and clinicians with a major interest in thyroid cancer, formed the International Thyroid Oncology Group (ITOG). The ITOG administration is based at Washington University and its primary mission, and the specific aim of this grant, is twofold: to provide educational programs, which will stimulate new ideas for research in thyroid cancer and to provide clinicians with the clinical research skills, necessary to provide the best care for their patients. Great emphasis will be placed on assuring that the educational programs are based on the most relevant basic and clinical science topics in thyroid cancer and that the selected speakers are experts in their field. The educational programs will include: didactic lectures, group discussions, and poster sessions. The educational programs will be open to basic scientists, clinicians, postdoctoral trainees and patient advocates.

描述（由申请人提供）： “甲状腺癌研究和治疗新方向”系列教育方案的长期目标是为基础和临床科学家提供对甲状腺癌生物学和临床护理重要进展的了解。 有几个原因可以说明为什么这一主题的重点教育倡议是及时和必要的。 2007年，美国将有大约30，000例甲状腺癌新发病例。 人们可能认为这种恶性肿瘤是一种罕见的疾病，然而，由于未知的原因，甲状腺癌的发病率比任何其他实体瘤的发病率都要快。 最重要的是，在过去的二十年中，已经确定了导致甲状腺癌主要组织学类型的突变或染色体重排。 这些和其他实体瘤中的类似发现刺激了制药行业开发治疗剂，其靶向基因突变或由突变激活的代谢途径。 一些针对甲状腺癌的靶向治疗已经在临床前研究中显示出活性，甚至在早期临床试验中。 这些新疗法对局部晚期或转移性甲状腺癌患者有很大的希望。 此外，这些疗法代表了“个性化基因组医学”的一个主要例子。 目前，没有任何社会或协会将发展和提供甲状腺癌教育计划作为其主要使命。 两年前，认识到需要开展广泛的甲状腺癌教育项目，一群对甲状腺癌感兴趣的忠诚的基础科学家和临床医生成立了国际甲状腺肿瘤学小组（ITOG）。 ITOG管理部门设在华盛顿大学，其主要使命和该补助金的具体目标是双重的：提供教育计划，这将激发甲状腺癌研究的新思路，并为临床医生提供临床研究技能，为患者提供最佳护理。 将非常重视确保教育计划是基于甲状腺癌最相关的基础和临床科学主题，并且选定的演讲者是他们领域的专家。 教育计划将包括：教学讲座，小组讨论和海报会议。这些教育项目将向基础科学家、临床医生、博士后学员和患者倡导者开放。